Healthy AdultNCT07659834
Food Supplement for Longevity
A study testing Longevity supplement in people with Healthy Adult and Longevity, run by Sam Treadway at 1 site in United Kingdom.
Trial summary
As we age, the cells in our body gradually lose their ability to produce energy efficiently and repair damage. This process, known as cellular ageing, is linked to lower levels of a molecule called Nicotinamide Adenine Dinucleotide (NAD⁺), which is essential for energy production and maintaining healthy cell function. Read more about this study
- Who is it for?
- Ages 35 years and olderHealthy volunteers can take part
- Conditions the study is for
- Healthy Adult, Longevity
- What is being tested?
- Longevity supplement
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 18 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 6 Mar 2026to 1 Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participant has provided written informed consent before participating in the study after being given a full description of the study and prior to any study-specific procedures being performed.
- Participant has no significant medical diagnosis (health individuals)
- Participant takes no regular prescription medication
- Participant is not undertaking any restrictive diet (e.g. Carnivore, Low FODMAP)
- Participant agrees to adhere to guidance on fortified food intake for the duration of the study
- Participant is a male or non-pregnant female and is ≥35 years of age
Show all 9Show fewer
- If WOCBP participant is willing to adhere to one of the following methods of contraception i) Hormonal contraception e.g. the 'pill' or an implant ii) Intrauterine device (IUD) iii) Intrauterine hormone-releasing system (IUS) iv) Hysterectomy v) Vasectomised partner vi) Sexual abstinence (if it is in line with your preferred and usual lifestyle).
- Participant can communicate well with the Investigator and to comply with the requirements for the entire study.
- Participant has a body mass index (BMI) of 18.5 - 39.9kg/m2 (bounds included).
Who cannot join
- Participant has consumed nutritional supplement, that in the opinion of the investigator may affect any of the study primary or secondary endpoints, in the past 3 months
- Diagnosis of any current medical condition that requires regular prescription medication or at the discretion of the investigator may affect study endpoints
- Participated in a trial of an investigational medical product or medical device in the last 28 days.
- Females who report to be pregnant or lactating
- Unwilling to maintain a stable diet for the duration of the trial.
- Unwilling to consume <5 portions per week fortified food per week
Show all 12Show fewer
- History of drug or alcohol abuse
- Alcohol use >2 standard servings/day
- Being in the opinion of the investigator unsuitable, in the circumstance where patient safety of scientific value of the study may be affected i.e. unable to swallow capsules, phobia to needles, significant travel that would affect adhereance study participation etc
- Hypersensitivity to any component of the supplement
- Previously identified niacin deficiency
- Participant is involved in this study as an Investigator, sub-Investigator, study coordinator or other delegated study team members.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Open Label Study to Assess the Effect of a Food Supplement on Markers of Cellular Ageing and Longevity
As we age, the cells in our body gradually lose their ability to produce energy efficiently and repair damage. This process, known as cellular ageing, is linked to lower levels of a molecule called Nicotinamide Adenine Dinucleotide (NAD⁺), which is essential for energy production and maintaining healthy cell function. Other factors, such as reduced antioxidant capacity and mitochondrial decline, also contribute to ageing.
This study will explore whether a daily food supplement, taken for one month, can improve markers of cellular health in adults aged 35 and over. Thrive⁺ contains ingredients that may support energy metabolism and antioxidant defences, including compounds that boost NAD⁺ levels and Coenzyme Q10 (CoQ10), which helps cells produce energy. It also includes resveratrol, a plant compound thought to promote healthy ageing.
Read more
The research will take place at The Functional Gut Clinic in Manchester and will involve 15 healthy volunteers. Participants will attend two clinic visits: one at the start and one after 30 days of supplementation. At each visit, they will have blood tests, blood pressure and heart rhythm checks, a simple grip strength test, and complete short questionnaires on mood and wellbeing. Women of childbearing potential will also have a pregnancy test. The supplement will be taken as one capsule per day for 30 days.
The main question is whether the supplement increases NAD⁺ levels in the blood. We will also look at other markers, such as antioxidant status, inflammation, and physical measures like grip strength. The study aims to provide insight into whether supplementation can support healthy ageing in everyday life.
- Conditions
- Healthy Adult, Longevity
- Being tested
- Longevity supplement
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Longevity supplementDietary supplement
Supplement containing Niagen NR 300mg, Trans resveratrol 250mg, Niacin (B3) 120mg, CoEnzyme Q10 100mg and Copper 0.3mg. Taken once daily.
| Study group | Role | What they receive |
|---|---|---|
| Longevity supplement | Experimental | This is a single arm study, with the a participants receiving the active supplement. Supplement containing Niagen NR 300mg, Trans resveratrol 250mg, Niacin (B3) 120mg, CoEnzyme Q10 100mg and Copper 0.3mg. Taken once daily. Receives: Dietary Supplement: Longevity supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in whole blood nicotinamide adenine dinucleotide (NAD+)
Change in whole blood NAD+ measured using Liquid chromatography mass spectrometry. Changes measured from baseline (pre supplement) to end of study (30 days of supplementation). measured in micrograms per millilitre.
Measured: 30 days
Secondary outcomes (3)
Change in plasma NAD+ metabolites
Changes in plasma NAD+ metabolites. These include changes in Nicotinamide (NAM) and 1-Methylnicotinamide. These are both measures in milligrams (mg) using Liquid chromatography mass spectrometry. Changes to be measured from baseline to end of study.
Measured: 30 days
Change in total coenzyme Q10 (CoQ10)
Changes in plasma coenzyme Q10. This is measured in micrograms (ug) using colourimetry. Changes to be measured from baseline to end of study.
Measured: 30 days
Change in standard haematology and biochemistry blood panels
Changes in haematology and biochemistry blood panels. Changes till be assessed by a study doctor and assigned any clinical significance. Any clinical significant findings will be recorded as an adverse event. Changes will be measured from baseline to end of study.
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2026
- Study start6 Mar 2026
- Primary completion12 Jun 2026
- Study completion1 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy AdultStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 18 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sam Treadway
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Sam Treadway, The Functional Gut Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07659834
- Sponsor's protocol ID
- FGC-26-03
- Status last verified
- Jun 2026
- First submitted
- 15 Jun 2026
- Last updated
- 22 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open Label Study to Assess the Effect of a Food Supplement on Markers of Cellular Ageing and Longevity
- ClinicalTrials.gov ID
- NCT07659834
- Acronym / sponsor ID
- FGC-26-03
- Conditions
- Healthy Adult, Longevity
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 18 participants (actual)
- Lead sponsor
- Sam TreadwayUniversity, hospital or other
- Study start
- 6 Mar 2026 (actual)
- Primary completion
- 12 Jun 2026 (actual)
- Study completion
- 1 Aug 2026 (estimated)
- First posted
- 22 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
As we age, the cells in our body gradually lose their ability to produce energy efficiently and repair damage. This process, known as cellular ageing, is linked to lower levels of a molecule called Nicotinamide Adenine Dinucleotide (NAD⁺), which is essential for energy production and maintaining healthy cell function. Other factors, such as reduced antioxidant capacity and mitochondrial decline, also contribute to ageing.
This study will explore whether a daily food supplement, taken for one month, can improve markers of cellular health in adults aged 35 and over. Thrive⁺ contains ingredients that may support energy metabolism and antioxidant defences, including compounds that boost NAD⁺ levels and Coenzyme Q10 (CoQ10), which helps cells produce energy. It also includes resveratrol, a plant compound thought to promote healthy ageing.
The research will take place at The Functional Gut Clinic in Manchester and will involve 15 healthy volunteers. Participants will attend two clinic visits: one at the start and one after 30 days of supplementation. At each visit, they will have blood tests, blood pressure and heart rhythm checks, a simple grip strength test, and complete short questionnaires on mood and wellbeing. Women of childbearing potential will also have a pregnancy test. The supplement will be taken as one capsule per day for 30 days.
The main question is whether the supplement increases NAD⁺ levels in the blood. We will also look at other markers, such as antioxidant status, inflammation, and physical measures like grip strength. The study aims to provide insight into whether supplementation can support healthy ageing in everyday life.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Longevity supplement | Experimental | Dietary Supplement: Longevity supplementThis is a single arm study, with the a participants receiving the active supplement. Supplement containing Niagen NR 300mg, Trans resveratrol 250mg, Niacin (B3) 120mg, CoEnzyme Q10 100mg and Copper 0.3mg. Taken once daily. |
Who may qualify
- Ages
- 35 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Participant has provided written informed consent before participating in the study after being given a full description of the study and prior to any study-specific procedures being performed.
- Participant has no significant medical diagnosis (health individuals)
- Participant takes no regular prescription medication
- Participant is not undertaking any restrictive diet (e.g. Carnivore, Low FODMAP)
- Participant agrees to adhere to guidance on fortified food intake for the duration of the study
Key exclusion criteria (12 listed)
- Participant has consumed nutritional supplement, that in the opinion of the investigator may affect any of the study primary or secondary endpoints, in the past 3 months
- Diagnosis of any current medical condition that requires regular prescription medication or at the discretion of the investigator may affect study endpoints
- Participated in a trial of an investigational medical product or medical device in the last 28 days.
- Females who report to be pregnant or lactating
- Unwilling to maintain a stable diet for the duration of the trial.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Longevity supplementSupplement containing Niagen NR 300mg, Trans resveratrol 250mg, Niacin (B3) 120mg, CoEnzyme Q10 100mg and Copper 0.3mg. Taken once daily. | Dietary supplement | Longevity supplement |
Primary outcome
Change in whole blood nicotinamide adenine dinucleotide (NAD+)
Time frame: 30 days
Change in whole blood NAD+ measured using Liquid chromatography mass spectrometry. Changes measured from baseline (pre supplement) to end of study (30 days of supplementation). measured in micrograms per millilitre.
3 secondary outcomes
Change in plasma NAD+ metabolites
Time frame: 30 days
Change in total coenzyme Q10 (CoQ10)
Time frame: 30 days
Change in standard haematology and biochemistry blood panels
Time frame: 30 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Healthy Adult
RecruitingPhase 1
A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)
Healthy
Not yet recruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older Adults
Alzheimer Disease
Not yet recruiting
Nutrition Intervention for Older Adults and Research Training
Impaired Mobility
Active, not recruitingPhase 1
Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years
Pneumonia, Bacterial
Not yet recruiting
Comparison Between Eccentric Hamstring Training and Sprint-Specific Training
Healthy Adult, Athlete
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Longevity supplement in people with Healthy Adult and Longevity, run by Sam Treadway at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 22 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in whole blood nicotinamide adenine dinucleotide (NAD+) (time frame: 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2026.